Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Surya K. De*

DOI: 10.2174/1871530323666230220123228

DownloadDownload PDF Flyer Cite As
Novel 2,4- diaminopyrimidine 5-carboxamides as c-Jun N-terminal Kinase Inhibitors for Treating the Liver Fibrotic Disorder

Page: [1118 - 1123] Pages: 6

  • * (Excluding Mailing and Handling)

Abstract

Diaminopyrimidine compounds having the following general structure (I), compositions comprising an effective amount of a diaminopyrimidine compound, and methods for treating or preventing fibrotic liver disorders or other diseases associated with the JNK pathway are discussed in this patent study.

[1]
Thameem, D.S.; Kaur, C.; Ling, E.A. Microglial activation and its implications in the brain diseases. Curr. Med. Chem., 2007, 14(11), 1189-1197.
[http://dx.doi.org/10.2174/092986707780597961] [PMID: 17504139]
[2]
Cohen, P. Protein kinases — the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 2002, 1(4), 309-315.
[http://dx.doi.org/10.1038/nrd773] [PMID: 12120282]
[3]
Kluwe, J.; Pradere, J.P.; Gwak, G.Y.; Mencin, A.; De Minicis, S.; Österreicher, C.H.; Colmenero, J.; Bataller, R.; Schwabe, R.F. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology, 2010, 138(1), 347-359.
[http://dx.doi.org/10.1053/j.gastro.2009.09.015] [PMID: 19782079]
[4]
Vallerie, S.N.; Hotamisligil, G.S. The role of JNK proteins in metabolism. Sci. Transl. Med., 2010, 2(60), 60rv5.
[http://dx.doi.org/10.1126/scitranslmed.3001007] [PMID: 21123811]
[5]
Kodama, Y.; Kisseleva, T.; Iwaisako, K.; Miura, K.; Taura, K.; De Minicis, S.; Österreicher, C.H.; Schnabl, B.; Seki, E.; Brenner, D.A. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology, 2009, 137(4), 1467-1477.e5.
[http://dx.doi.org/10.1053/j.gastro.2009.06.045] [PMID: 19549522]
[6]
Virkamäki, A.; Ueki, K.; Kahn, C.R. Protein–protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J. Clin. Invest., 1999, 103(7), 931-943.
[http://dx.doi.org/10.1172/JCI6609] [PMID: 10194465]
[7]
Wang, M.C.; Bohmann, D.; Jasper, H. JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell, 2005, 121(1), 115-125.
[http://dx.doi.org/10.1016/j.cell.2005.02.030] [PMID: 15820683]
[8]
Garg, R.; Kumariya, S.; Katekar, R.; Verma, S.; Goand, U.K.; Gayen, J.R. JNK signaling pathway in metabolic disorders: An emerging therapeutic target. Eur. J. Pharmacol., 2021, 901, 174079.
[http://dx.doi.org/10.1016/j.ejphar.2021.174079] [PMID: 33812885]
[9]
Wang, Y.; Hamang, M.; Culver, A.; Jiang, H.; Yanum, J.; Garcia, V.; Lee, J.; White, E.; Kusumanchi, P.; Chalasani, N.; Liangpunsakul, S.; Yaden, B.C.; Dai, G. Activin B promotes the initiation and progression of liver fibrosis. Hepatol. Commun., 2022, 6(10), 2812-2826. Epub ahead of print
[http://dx.doi.org/10.1002/hep4.2037] [PMID: 35866567]
[10]
Wang, W.; Gao, W.; Zhu, Q.; Alasbahi, A.; Seki, E.; Yang, L. TAK1: A molecular link between liver inflammation, fibrosis, steatosis, and carcinogenesis. Front. Cell Dev. Biol., 2021, 9, 734749.
[http://dx.doi.org/10.3389/fcell.2021.734749] [PMID: 34722513]
[11]
Stebbins, J.L.; De, S.K.; Machleidt, T.; Becattini, B.; Vazquez, J.; Kuntzen, C.; Chen, L.H.; Cellitti, J.F.; Riel-Mehan, M.; Emdadi, A.; Solinas, G.; Karin, M.; Pellecchia, M. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl. Acad. Sci., 2008, 105(43), 16809-16813.
[http://dx.doi.org/10.1073/pnas.0805677105] [PMID: 18922779]
[12]
De, S.K.; Stebbins, J.L.; Chen, L.H.; Riel-Mehan, M.; Machleidt, T.; Dahl, R.; Yuan, H.; Emdadi, A.; Barile, E.; Chen, V.; Murphy, R.; Pellecchia, M. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J. Med. Chem., 2009, 52(7), 1943-1952.
[http://dx.doi.org/10.1021/jm801503n] [PMID: 19271755]
[13]
Maik-Rachline, G.; Wortzel, I.; Seger, R. Alternative splicing of MAPKs in the regulation of signaling specificity. Cells, 2021, 10(12), 3466.
[http://dx.doi.org/10.3390/cells10123466] [PMID: 34943973]
[14]
Xu, W.; Kannan, S.; Verma, C.S.; Nacro, K. Update on the development of MNK inhibitors as therapeutic agents. J. Med. Chem., 2022, 65(2), 983-1007.
[http://dx.doi.org/10.1021/acs.jmedchem.1c00368] [PMID: 34533957]
[15]
Zhao, Y.; Kuca, K.; Wu, W.; Wang, X.; Nepovimova, E.; Musilek, K.; Wu, Q. Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases. Alzheimers Dement., 2022, 18(1), 152-158.
[http://dx.doi.org/10.1002/alz.12370] [PMID: 34032377]
[16]
Madrid, M.; Gómez-Gil, E.; Cansado, J. Negative control of cytokinesis by stress-activated MAPK signaling. Curr. Genet., 2021, 67(5), 715-721.
[http://dx.doi.org/10.1007/s00294-021-01155-6] [PMID: 33791858]
[17]
Wang, J.; Tai, G. Role of C-Jun N-terminal kinase in hepatocellular carcinoma development. Target. Oncol., 2016, 11(6), 723-738.
[http://dx.doi.org/10.1007/s11523-016-0446-5] [PMID: 27392951]
[18]
Hammouda, M.; Ford, A.; Liu, Y.; Zhang, J. The JNK signaling pathway in inflammatory skin disorders and cancer. Cells, 2020, 9(4), 857.
[http://dx.doi.org/10.3390/cells9040857] [PMID: 32252279]
[19]
Singh, R.K.; Najmi, A.K. Novel therapeutic potential of mitogen-activated protein kinase activated protein kinase 2 (mk2) in chronic airway inflammatory disorders. Curr. Drug Targets, 2019, 20(4), 367-379.
[http://dx.doi.org/10.2174/1389450119666180816121323] [PMID: 30112991]
[20]
Grynberg, K.; Ma, F.Y.; Nikolic-Paterson, D.J. The JNK signaling pathway in renal fibrosis. Front. Physiol., 2017, 8, 829.
[http://dx.doi.org/10.3389/fphys.2017.00829] [PMID: 29114233]
[21]
Kasuya, Y.; Kim, J.D.; Hatano, M.; Tatsumi, K.; Matsuda, S. Pathophysiological roles of stress-activated protein kinases in pulmonary fibrosis. Int. J. Mol. Sci., 2021, 22(11), 6041.
[http://dx.doi.org/10.3390/ijms22116041] [PMID: 34204949]
[22]
Seki, E.; Brenner, D.A.; Karin, M. A liver full of JNK: Signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology, 2012, 143(2), 307-320.
[http://dx.doi.org/10.1053/j.gastro.2012.06.004] [PMID: 22705006]